A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-12

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety of combining Osimertinib with either Cisplatin or Carboplatin (at different dose levels) and Etoposide, to find out what effects, if any, this combination of drugs has on people with EGFR mutant lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

NCT03810807

Metastatic Non-small Cell Lung Cancer

COMPLETED PHASE1

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796

Metastatic Non-small Cell Lung Cancer

RECRUITING PHASE2

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097

Non-small Cell Lung Cancer

RECRUITING PHASE3

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

NCT06436144

Non Small Cell Lung Cancer EGFR Gene Mutation Non Small Cell Lung Cancer Stage IIIB +1 more

NOT_YET_RECRUITING PHASE2

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

NCT06918782

Lung Cancer (NSCLC)

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide

Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)

Group Type EXPERIMENTAL

Osimertinib

Intervention Type DRUG

Osimertinib 80mg daily

Platinum

Intervention Type DRUG

Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4

Etoposide

Intervention Type DRUG

Etoposide 100mg/m2 or Etoposide 80mg/m2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Osimertinib

Osimertinib 80mg daily

Intervention Type DRUG

Platinum

Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4

Intervention Type DRUG

Etoposide

Etoposide 100mg/m2 or Etoposide 80mg/m2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Advanced biopsy-proven metastatic non-small cell lung cancer
* Either have not started an EGFR TKI or may have started osimertinib within the last 9 weeks
* Somatic activating mutation in EGFR in pre-treatment tumor biopsy or cfDNA
* Evidence of a concurrent P53 alteration by IHC or NGS on pre-treatment tumor biopsy or cfDNA
* Evidence of a concurrent RB1 alteration by IHC or NGS on pre-treatment tumor biopsy or cfDNA
* Must have a site of disease amenable to repeat biopsy and be willing to undergo a biopsy during treatment
* Measurable (RECIST 1.1) indicator lesion not previously irradiated
* Karnofsky performance status (KPS) ≥ 70%
* Age \>18 years old
* Ability to swallow oral medication
* Adequate organ function

* AST, ALT ≤ 3 x ULN
* Total bilirubin ≤ 1.5x ULN
* Creatinine ≤ 1.5x ULN OR calculated creatinine clearance ≥ 60ml/min
* Absolute neutrophil count (ANC) ≥ 1000 cells/mm\^3
* Hemoglobin≥8.0 g/dL
* Platelets ≥100,000/mm\^3

Exclusion Criteria

* Pregnant or lactating women
* Started an EGFR TKI other than osimertinib or started osimertinib more than 9 weeks ago
* Any radiotherapy within 1 week of starting treatment on protocol.
* Any major surgery within 1 weeks of starting treatment on protocol.
* Any evidence of active clinically significant interstitial lung disease
* Continue to have unresolved \> grade 1 toxicity from any previous treatment
* Have pure small cell histology
* Corrected QT interval using Fridericia's formula (QTcF)\>475msec or any clinically significant (as deemed by the investigator) abnormalities in rhythm or conduction or morphology of the resting EKG.
* Patients are to be excluded from cisplatin treatment arm if they meet any of the following criteria:
* Creatinine clearance \< 60 ml/min
* Hearing impairment requiring assistive device
* Neuropathy
* The treating provider does not feel as though the patient should receive cisplatin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No